Proceedings of the Standing Senate Committee on
Social Affairs, Science and Technology

Issue 11 - Eighth Report of the Committee

Tuesday, April 8, 2014

The Standing Senate Committee on Social Affairs, Science and Technology has the honour to present its

EIGHTH REPORT

Your committee, which was authorized by the Senate on Tuesday, November 19, 2013 to examine and report on prescription pharmaceuticals in Canada, respectfully requests funds for the fiscal year ending March 31, 2015.

Pursuant to Chapter 3:06, section 2(1)(c) of the Senate Administrative Rules, the budget submitted to the Standing Committee on Internal Economy, Budgets and Administration and the report thereon of that committee are appended to this report.

Respectfully submitted,

KELVIN K. OGILVIE

Chair

STANDING SENATE COMMITTEE ON
SOCIAL AFFAIRS, SCIENCE AND TECHNOLOGY

SPECIAL STUDY ON PRESCRIPTION PHARMACEUTICALS IN CANADA

APPLICATION FOR BUDGET AUTHORIZATION
FOR THE FISCAL YEAR ENDING MARCH 31, 2015

Extract from the Journals of the Senate, Tuesday, November 19, 2013:

The Honourable Senator Ogilvie moved, seconded by the Honourable Senator Runciman:

That the Standing Senate Committee on Social Affairs, Science and Technology be authorized to examine and report on prescription pharmaceuticals in Canada, including but not limited to:

(a) the process to approve prescription pharmaceuticals with a particular focus on clinical trials;

(b) the post-approval monitoring of prescription pharmaceuticals;

(c) the off-label use of prescription pharmaceuticals; and

(d) the nature of unintended consequences in the use of prescription pharmaceuticals.

That the papers and evidence received and taken and work accomplished by the committee on this subject during the First Session of the Forty-first Parliament be referred to the committee; and

That the committee submit its final report no later than December 31, 2014 and that the committee retain until March 31, 2015, all powers necessary to publicize its findings.

After debate,

The question being put on the motion, it was adopted.

Gary W. O'Brien

Clerk of the Senate

SUMMARY OF BUDGET

The above budget was approved by the Standing Senate Committee on the Standing Senate Committee on Social Affairs, Science and Technology on March 5, 2014.

The undersigned or an alternate will be in attendance on the date that this budget is considered.

___________________________________________________________________________
Date                Kelvin K. Ogilvie
                       Chair, Standing Senate Committee on Social Affairs, Science and Technology

___________________________________________________________________________
Date                Noël A. Kinsella
                       Chair, Standing Committee on Internal Economy, Budgets and Administration

HISTORICAL INFORMATION

Expenses 2012-2013	$ 15,441
Expenses 2013-1014	$ 6,370

GENERAL ESTIMATE OF THE TOTAL COST
OF THE SPECIAL STUDY

Pursuant to Chapter 3:06, section 2(2) of the Senate Administrative Rules, the total estimated cost for this study, including this budget, is $42,281.

STANDING SENATE COMMITTEE ON
SOCIAL AFFAIRS, SCIENCE AND TECHNOLOGY

SPECIAL STUDY ON PRESCRIPTION PHARMACEUTICALS IN CANADA

EXPLANATION OF BUDGET ITEMS
APPLICATION FOR BUDGET AUTHORIZATION
FOR THE FISCAL YEAR ENDING MARCH 31, 2015

The Senate administration has reviewed this budget application.

______________________________________________________________________
Heather Lank, Principal Clerk, Committees Directorate                    Date

______________________________________________________________________
Nicole Proulx, Director of Finance and Procurement                         Date

APPENDIX (B) TO THE REPORT

Thursday, April 3, 2014

The Standing Committee on Internal Economy, Budgets and Administration has examined the budget presented to it by the Standing Senate Committee on Social Affairs, Science and Technology for the proposed expenditures of the said Committee for the fiscal year ending March 31, 2015, for the purpose of its special study on prescription pharmaceuticals, as authorized by the Senate on Tuesday, November 19, 2013. The said budget is as follows:

General Expenses	$ 20,470
TOTAL	$ 20,470

Respectfully submitted,

NOËL A. KINSELLA

Chair